Shares of Bristol Myers Squibb Co. BMY rose 1.47% to $55.79 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to ...
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools ...
A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s ...
Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...
People with blood cancer to benefit from innovative new treatment on the NHS - The type of Car T-cell therapy involves taking ...
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...
For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with ...
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback